Innate immunity in pancreatic cancer: Lineage tracing and function

Front Immunol. 2023 Jan 16:13:1081919. doi: 10.3389/fimmu.2022.1081919. eCollection 2022.


Increasingly, patients with gastrointestinal tumors can benefit from immunotherapy, but not patients with pancreatic cancer. While this lack of benefit has been attributed to lower T-cell infiltration in pancreatic cancer, other studies have demonstrated the presence of numerous T cells in pancreatic cancer, suggesting another mechanism for the poor efficacy of immunotherapy. Single-cell RNA sequencing studies on the pancreatic cancer immune microenvironment have demonstrated the predominance of innate immune cells (e.g., macrophages, dendritic cells, mast cells, and innate immune lymphoid cells). Therefore, in-depth research on the source and function of innate immune lymphocytes in pancreatic cancer could guide pancreatic cancer immunotherapy.

Keywords: innate immune lymphocyte; innate immunity; lineage tracing; pancreatic cancer; tumor immune microenvironment.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Immunity, Innate
  • Immunotherapy
  • Pancreatic Neoplasms*
  • T-Lymphocytes
  • Tumor Microenvironment

Grants and funding

This study was jointly supported by the National Natural Science Foundation of China (82173091 to LY 81972693 to WC), Shanghai Pujiang Program (2021PJD014 to LY), Research Project of Shanghai Municipal Health Commission (20214Y0396 to LY), Zhejiang Provincial Nature Science Foundation of China (LR20H160001 to WC), Key R&D projects of Zhejiang Province (2021C03012 to WC), Young Qihuang Scholar of National Administration of Traditional Chinese Medicine (to WC), Zhejiang Provincial Ten Thousand Plan for Young Top Talents (2018, to WC), Training objects of health innovative talents of Zhejiang Health (2018, to WC). The funding agencies had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.